


Gross et al., "Antitumor Activity of the Glutaminase Inhibitor CB-839 in TNBC"  
Supplementary Figure S7



**Supplementary Figure S7. Oral dosing of CB-839 results in high exposure in mouse plasma and is well tolerated in immunocompromised mice.** A, plasma levels of CB-839 measured by LC/MS/MS following a single oral dose at 50 mg/kg CB-839 administered to female Scid/Bg mice. B, body weights measured in a TNBC patient-derived xenograft model (N=10 per group) dosed orally with vehicle or 200 mg/kg CB-839 twice daily (BID) for 28 days (efficacy study in Fig. 6E). C, body weights measured in a JIMT-1 cell line xenograft model as in (B) but with two additional cohorts: paclitaxel at 10 mg/kg given as an intravenous bolus every other day for 5 doses administered alone or in combination with CB-839 (efficacy study in Fig. 6F). For (B) and (C) the percent change in body weight relative to the predose value is plotted.